Area of peripheral retinal nonperfusion and treatment response in branch and central retinal vein occlusion

Retina. 2014 Sep;34(9):1736-42. doi: 10.1097/IAE.0000000000000148.

Abstract

Purpose: To evaluate the extent of peripheral retinal nonperfusion in retinal vein occlusion and to determine its effect on the severity of macular edema and response to treatment.

Methods: This prospective clinic-based cohort study included 32 consecutive patients with retinal vein occlusion and refractory macular edema evaluated using spectral domain optical coherence tomography and wide-field fluorescein angiography. Areas of ischemia were calculated as a percentage of the total visible retina (ischemic index), which was evaluated when macular edema was present (foveal central subfield >300 μm) and when edema had resolved (foveal central subfield ≤ 300 μm). Ischemic index was the main outcome measure.

Results: The mean ischemic index at study enrollment was 14.8% and was larger when macular edema was present compared with when edema had resolved (14.8 vs. 10.3%, P < 0.001). Compared with those with less nonperfusion, patients with ischemic index >10% had thicker mean foveal central subfield on optical coherence tomography (520.8 vs. 424.5 μm, P = 0.029) and worse visual acuity (56.3 vs. 59 letters) with the presence of macular edema and experienced greater decrease in optical coherence tomography (296.1 vs. 165.3 μm, P = 0.019) and gain in visual acuity (12.4 vs. 0.9 letters, P = 0.036) in response to treatment.

Conclusion: The area of peripheral retinal nonperfusion is variable in patients with retinal vein occlusion and affects its clinical course and response to treatment.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Cohort Studies
  • Dexamethasone / administration & dosage*
  • Drug Implants
  • Drug Therapy, Combination
  • Female
  • Fluorescein Angiography
  • Humans
  • Intravitreal Injections
  • Ischemia / physiopathology
  • Macular Edema / drug therapy
  • Macular Edema / physiopathology
  • Male
  • Middle Aged
  • Prospective Studies
  • Ranibizumab
  • Retinal Vein / physiopathology*
  • Retinal Vein Occlusion / drug therapy*
  • Retinal Vein Occlusion / physiopathology*
  • Tomography, Optical Coherence
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity / physiology

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Drug Implants
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Dexamethasone
  • Ranibizumab